keyword
MENU ▼
Read by QxMD icon Read
search

Xelox

keyword
https://www.readbyqxmd.com/read/28917648/challenges-of-conducting-a-prospective-clinical-trial-for-older-patients-lessons-learned-from-ncctg-n0949-alliance
#1
Nadine J McCleary, Joleen Hubbard, Michelle R Mahoney, Jeffrey A Meyerhardt, Daniel Sargent, Alan Venook, Axel Grothey
OBJECTIVES: While the risk of developing colorectal cancer increases with age, there are limited prospective data regarding best treatment in the older adult population. We launched a phase III trial to evaluate difference in treatment outcome for older adults (aged ≥70years) with advanced colorectal cancer. Here we review the challenges faced and reasons for poor accrual to N0949. MATERIALS AND METHODS: We describe the conceptualization, development and limited results of N0949, a randomized phase III study of fluoropyrimidine/bevacizumab with or without oxaliplatin (mFOLFOX7 or XELOX) as first line chemotherapy for metastatic colorectal cancer...
September 13, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28906589/neoadjuvant-therapy-of-bevacizumab-in-combination-with-oxaliplatin-and-capecitabine-xelox-for-patients-with-metastatic-colorectal-cancer-with-unresectable-liver-metastases-a-phase-ii-open-label-single-arm-noncomparative-trial
#2
Hong-Hwa Chen, Jen-Kou Lin, Joe-Bin Chen, Chieh-Han Chuang, Mei-Ching Liu, Jen-Yi Wang, Chung-Rong Changchien
AIM: This phase II, open-label study evaluated the efficacy and safety of neoadjuvant therapy with bevacizumab plus XELOX (capecitabine and oxaliplatin) for untreated metastatic colorectal cancer with unresectable liver metastases and assessed conversion of unresectable to resectable metastases after neoadjuvant treatment. METHODS: Patients received bevacizumab 5 mg/kg and oxaliplatin 85 mg/m(2) on day 1, and capecitabine 1000 mg/m(2) twice daily on days 1-5 followed by 2 days of rest in a 14-day cycle for 12 cycles; bevacizumab was excluded in cycles 6 and 7...
September 14, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28900996/-clinicopathologic-characteristics-and-prognosis-of-gastric-hepatoid-adenocarcinoma
#3
Rongfei Zhao, Xinxin Wang, Xin Lan, Mingsen Li
OBJECTIVE: To investigate the clinicopathological characteristics, diagnosis, treatment and prognosis of gastric hepatoid adenocarcinoma(HAS). METHODS: Retrospective analysis of clinicopathological data of 24 cases with gastric HAS diagnosed by surgery and pathology in Chinese PLA General Hospital from January 2013 to May 2016 were carried out. All the patients underwent preoperative serum alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), endoscopy and imaging examination (CT or B-mode ultrasonography), and those with elevated AFP were excluded from liver cancer, cirrhosis, endodermal sinus tumor and other diseases...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28900499/profiling-chemotherapy-associated-myelotoxicity-among-chinese-gastric-cancer-population-receiving-cytotoxic-conventional-regimens-epidemiological-features-timing-predictors-and-clinical-impacts
#4
Ci Zhu, Yan Wang, Xicheng Wang, Chunmei Bai, Dan Su, Bing Cao, Jianming Xu
Objectives: We aim to evaluate the epidemiological features, timing, predictors and clinical impacts of chemotherapy-associated myelotoxicity in Chinese gastric cancer population receiving six established cytotoxic conventional regimens (CF/XP, EC(O)F/EC(O)X, DC(O)F/DC(O)X, PC(O)F/PC(O)X, FOLFOX4, or mFOLFOX7/XELOX). Patients and methods: A 4-year multicenter, prospective, observational study was conducted in multiple hospitals/institutes spanning three major regions in China. A total of 1,285 patients with gastric cancer, treated with six selected regimens between 2010 and 2014 were included...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28894576/first-line-chemotherapy-with-capecitabine-oxaliplatin-for-advanced-gastric-cancer-a-phase-i-study
#5
Hironaga Satake, Hisateru Yasui, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Masahito Kotaka, Takeshi Kato, Akihito Tsuji
Combination chemotherapy with capecitabine and oxaliplatin for gastric cancer (G-XELOX) is considered as a potentially promising regimen. However, the use of the G-XELOX regimen in Japanese patients has not been investigated to date, and recommended doses of G-XELOX for Japanese patients with metastatic gastric cancer have not been established. The aim of the present study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) for systemic chemotherapy with G-XELOX for metastatic gastric cancer...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28874597/risk-of-febrile-neutropenia-associated-with-select-myelosuppressive-chemotherapy-regimens-in-a-large-community-based-oncology-practice
#6
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H Page, Chun Chao
Background: NCCN has classified commonly used chemotherapy regimens into high (>20%), intermediate (10%-20%), or low (<10%) febrile neutropenia (FN) risk categories based primarily on clinical trial evidence. Many chemotherapy regimens, however, remain unclassified by NCCN or lack FN incidence data in real-world clinical practice. Patients and Methods: We evaluated incidence proportions of FN and grade 4 and 3/4 neutropenia during the first chemotherapy course among patients from Kaiser Permanente Southern California who received selected chemotherapy regimens without well-established FN risk...
September 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28860808/monocyte-to-lymphocyte-ratio-predicts-survival-in-patients-with-advanced-gastric-cancer-undergoing-neoadjuvant-chemotherapy
#7
Li Chen, Ying Hao, Lihua Zhu, Sen Li, Yanjiao Zuo, Yuxin Zhang, Hongjiang Song, Yingwei Xue
BACKGROUND: Currently, precise predictors in gastric cancer patients undergoing neoadjuvant chemotherapy are lacking. The study aims to investigate the prognostic value of the monocyte to lymphocyte ratio (MLR) in patients with advanced gastric cancer receiving S-1 plus oxaliplatin (SOX) or oxaliplatin and capecitabine (XELOX) neoadjuvant chemotherapy regimen. METHODS: The data from Harbin Medical University Cancer Hospital from August 2008 to September 2015 were retrospectively collected...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28766482/self-reported-adherence-to-capecitabine-on-xelox-treatment-as-adjuvant-therapy-for-colorectal-cancer
#8
Kazuyoshi Kawakami, Takashi Yokokawa, Kazuo Sugita, Takahito Sugisaki, Kenichi Suzuki, Mitsukuni Suenaga, Kensei Yamaguchi, Ayaka Inoue, Yoshiaki Machida, Toshiharu Yamaguchi, Toshihiro Hama
Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as adjuvant therapy for colorectal cancer. The main aim of this study was to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011 and April 30, 2015 at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research...
August 1, 2017: Oncology Research
https://www.readbyqxmd.com/read/28687001/clinical-efficacy-of-neoadjuvant-chemotherapy-regimens-fleeox-vs-xelox-in-patients-with-initially-unresectable-advanced-gastric-cancer-a-propensity-score-analysis
#9
Yang Li, Jun Chen, Qi He, Xiang Ji, Xulin Wang, Chaogang Fan, Guoli Li
PURPOSE: This study was designed to assess the effectiveness of FLEEOX (5-Fu, leucovorin, etoposide, oxaliplatin, and epirubicin) compared with XELOX (capecitabine and oxaliplatin) as neoadjuvant chemotherapy (NAC) for initially unresectable advanced gastric cancer (AGC). METHODS: This study reviewed patients who underwent FLEEOX or XELOX for initially unresectable AGC. To reduce the bias in patient selection, we conducted propensity score match (PSM) with 1:1 ratio...
June 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28668898/clinical-study-on-the-medical-value-of-combination-therapy-involving-adoptive-immunotherapy-and-chemotherapy-for-stage-iv-colorectal-cancer-comvi-study
#10
Yoichiro Yoshida, Masayasu Naito, Teppei Yamada, Naoya Aisu, Daibo Kojima, Toshiyuki Mera, Toshihiro Tanaka, Keiko Naito, Kosei Yasumoto, Takashi Kamigaki, Shigenori Gotoh, Shohta Kodama, Yuichi Yamashita, Suguru Hasegawa
BACKGROUND: Adoptive immunotherapy for cancer has evolved through development of novel technologies for generating a large number of activated killer cells, such as αβ T-cells, γδ T-cells, and natural killer cells. There has been no prospective trial of combination therapy involving adoptive immunotherapy and first-line chemotherapy for stage IV colorectal cancer. The present pilot study aimed to evaluate the safety and feasibility of combination therapy involving adoptive immunotherapy and chemotherapy for stage IV colorectal cancer (COMVI study)...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28668897/hepatectomy-for-liver-metastases-of-colorectal-cancer-after-adoptive-chemoimmunotherapy-using-activated-%C3%AE-%C3%AE-t-cells
#11
Fuminori Ishii, Yoichiro Yoshida, Yasushi Yamauchi, Naoya Aisu, Daibo Kojima, Toshiyuki Mera, Daisuke Kato, Toshihiro Tanaka, Keiko Naito, Kosei Yasumoto, Takashi Kamigaki, Shigenori Goto, Yoshihiro Hamada, Satoshi Nimura, Shohta Kodama, Suguru Hasegawa
BACKGROUND/AIM: Various types of chemoimmunotherapies for malignant tumors have been reported. However, there are few reports on hepatectomy after chemoimmunotherapy. We evaluated the safety and efficacy of hepatectomy for patients with stage IV colorectal liver metastases (CLM) after chemoimmunotherapy using activated αβ T-cells. PATIENTS AND METHODS: From June 2012 to December 2016, five patients who underwent hepatectomy after receiving capecitabine and oxaliplatin (XELOX) plus bevacizumab and ex vivo-expanded αβ T-lymphocytes as first-line chemoimmunotherapy were included...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28668863/phase-i-study-of-neoadjuvant-chemotherapy-with-capecitabine-and-oxaliplatin-for-locally-advanced-gastric-cancer
#12
Hironaga Satake, Masato Kondo, Motoko Mizumoto, Takeshi Kotake, Yoshihiro Okita, Takatsugu Ogata, Yukimasa Hatachi, Hisateru Yasui, Akira Miki, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
AIM: To determine the recommended dose of neoadjuvant chemotherapy of combined capecitabine and oxalipatin (G-XELOX) for locally advanced gastric cancer. PATIENTS AND METHODS: Patients received two cycles of neoadjuvant chemotherapy with oxaliplatin on day 1 and capecitabine (2,000 mg/m(2)/day, b.i.d.) on days 1-14, repeated every 3 weeks. They then underwent gastrectomy with curative D2/3 lymph-node dissection followed by adjuvant therapy with S-1 for 1 year. De-escalation of oxaliplatin dose was planned (starting at level 1, oxalipatin 130 mg/m(2))...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28599498/sequential-administration-of-xelox-and-xeliri-is-effective-feasible-and-well-tolerated-by-patients-with-metastatic-colorectal-cancer
#13
Taro Fukui, Koichi Suzuki, Kosuke Ichida, Yuji Takayama, Nao Kakizawa, Yuta Muto, Fumi Hasegawa, Fumiaki Watanabe, Rina Kikugawa, Masaaki Saito, Shingo Tsujinaka, Yasuyuki Miyakura, Toshiki Rikiyama
Sequential administration of the chemotherapy regimes capecitabine and oxaliplatin (XELOX) and capecitabine and irinotecan (XELIRI) in the first- to second-line treatment setting would allow patients to be managed more easily in an outpatient unit. However, a small number of studies have raised concerns of cumulative adverse events as a consequence of the continuous use of capecitabine. To investigate this, the present study conducted a retrospective review of 81 consecutive metastatic colorectal cancer (mCRC) patients treated with the oxaliplatin, fluorouracil and leucovorin-irinotecan, fluorouracil and leucovorin (FOLFOX-FOFIRI/F-F) regimen (n=40) or the XELOX-XELIRI (X-X) regimen (n=41) in first- to second-line chemotherapy in Saitama Medical Center between 2006 and 2012...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28553122/peripheral-venous-blood-neutrophil-to-lymphocyte-ratio-predicts-survival-in-patients-with-advanced-gastric-cancer-treated-with-neoadjuvant-chemotherapy
#14
Li Chen, Yanjiao Zuo, Lihua Zhu, Yuxin Zhang, Sen Li, Fei Ma, Yu Han, Hongjiang Song, Yingwei Xue
BACKGROUND: Accurate and useful predictors of gastric carcinoma treated with neoadjuvant chemotherapy are lacking at present. We aim to explore the potential prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) in advanced gastric cancer receiving S-1 plus oxaliplatin (SOX) or oxaliplatin and capecitabine (XELOX) regimen. METHODS: We enrolled 91 patients with advanced gastric cancer treated with neoadjuvant chemotherapy from August 2008 to September 2015...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28536340/-a-case-of-advanced-transverse-colon-cancer-with-nephrotic-syndrome-treated-with-curative-resection-and-complete-adjuvant-chemotherapy
#15
Nobutaka Sato, Seiya Fuyuno, Teppei Hatada, Takashi Furuhashi, Toshihiko Abe
A 74-year-old woman was diagnosed as having transverse colon cancer after diagnosis of nephrotic syndrome caused by membranous nephropathy. Although she had hypoproteinemia and hypoalbuminemia, we judged that she had no major nutritional problem. In previous, similar case reports, the use of human serum albumin and fresh-frozen plasma was suggested to be important to avoid complications in the perioperative period. Thus, we used the same in our patient in the perioperative period. In addition, we paid special attention to perioperative nutrition management and used total parenteral nutrition in perioperative period...
May 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28502421/is-neoadjuvant-chemoradiotherapy-always-necessary-for-mid-high-local-advanced-rectal-cancer-a-comparative-analysis-after-propensity-score-matching
#16
COMPARATIVE STUDY
Y Zhang, Y Sun, Z Xu, P Chi, X Lu
AIM: This study was aimed to compare perioperative and oncological outcomes of mid/high locally advanced midrectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (NCRT) vs. surgery alone, and to identify risk factors for local recurrence in mid/high LARC. METHOD: A total of 471 mid/high LARC patients treated with surgery alone or NCRT (50.4 Gy in 28 fractions) with concurrent FOLFOX/XELOX followed by TME in 6-8 weeks from 2008 to 2014 were matched 1:1 by using propensity score analysis...
August 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28419993/reduction-in-peripheral-cd19-cd24hcd27-b-cell-frequency-predicts-favourable-clinical-course-in-xelox-treated-patients-with-advanced-gastric-cancer
#17
Wei Li, Dongli Song, Hong Li, Li Liang, Naiqing Zhao, Tianshu Liu
BACKGROUND: Accumulating evidence suggests that regulatory B cells (Bregs) play an important role in modulating the immune response to tumours. Our previous study indicated that a small percentage of peripheral CD19+CD24hCD27+ Breg cells slowed gastric cancer progression in XELOX-treated patients. Here, we further investigated the relationship between dynamic changes in circulating Breg cells and the clinical course in XELOX-treated gastric cancer patients. METHODS: A total of 52 patients with advanced gastric cancer were enrolled in this study...
2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28391355/comparison-between-hypersensitivity-reactions-to-cycles-of-modified-folfox6-and-xelox-therapies-in-patients-with-colorectal-cancer
#18
COMPARATIVE STUDY
Hideki Ohta, Takahiro Hayashi, Sumie Murai, Hideyo Shiouchi, Yosuke Ando, Satomi Kumazawa, Kaori Ito, Yoshiaki Ikeda, Hiroshi Matsuoka, Kotaro Maeda, Kenji Kawada, Kimio Yasuda, Shigeki Yamada
PURPOSE: Although hypersensitivity reactions (HSRs) to oxaliplatin (L-OHP) therapy are well-documented, few reports have compared different therapies in terms of HSR occurrence. In this study, we compared the frequency and pattern of HSRs to modified FOLFOX6 (mFOLFOX6; 5-fluorouracil, levofolinate calcium and L-OHP infusions) and XELOX (capecitabine and L-OHP) therapies, and sought to identify risk factors associated with HSRs. METHODS: Patients who had received mFOLFOX6 or XELOX chemotherapeutic regimens for unresectable colon or rectal cancer or as adjuvant chemotherapy following colon cancer surgery between April 2012 and August 2015 were included...
May 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28327986/phase-iii-trial-comparing-3-6-months-of-adjuvant-folfox4-xelox-in-stage-ii-iii-colon-cancer-safety-and-compliance-in-the-tosca-trial
#19
S Lonardi, A Sobrero, G Rosati, M Di Bartolomeo, M Ronzoni, G Aprile, B Massida, M Scartozzi, M Banzi, M G Zampino, F Pasini, P Marchetti, M Cantore, A Zaniboni, L Rimassa, L Ciuffreda, D Ferrari, S Barni, V Zagonel, E Maiello, E Rulli, R Labianca
Background: Six months of oxaliplatin-based adjuvant chemotherapy is standard of care for radically resected stage III colon cancer and an accepted option for high-risk stage II. A shorter duration of therapy, if equally efficacious, would be advantageous for patients and Health Care Systems. Methods: TOSCA (“Randomized trial investigating the role of FOLFOX-4 or XELOX (3 versus 6 months) regimen duration and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer) is an open-label, phase III, multicenter, non-inferiority trial randomizing patients with high-risk stage II or stage III radically resected colon cancer to receive 3 months (arm 3m) vs 6 months (arm 6m) of FOLFOX4/XELOX...
February 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28279170/patients-with-pathological-stage-n2-rectal-cancer-treated-with-early-adjuvant-chemotherapy-have-a-lower-treatment-failure-rate
#20
Yan-Ru Feng, Jing Jin, Hua Ren, Xin Wang, Shu-Lian Wang, Wei-Hu Wang, Yong-Wen Song, Yue-Ping Liu, Yuan Tang, Ning Li, Xin-Fan Liu, Hui Fang, Zi-Hao Yu, Ye-Xiong Li
BACKGROUND: In this era of oxaliplatin-based adjuvant therapy, the optimal sequence in which chemoradiotherapy should be administered for pathological stage N2 rectal cancer is unknown. The aim of this study was to investigate this sequence. METHODS: In the primary adjuvant concurrent chemoradiotherapy (A-CRT) group (n = 71), postoperative concurrent chemoradiotherapy was administered before adjuvant chemotherapy. In the primary adjuvant chemotherapy (A-CT) group (n = 43), postoperative concurrent chemoradiotherapy was administered during or after adjuvant chemotherapy...
March 9, 2017: BMC Cancer
keyword
keyword
2278
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"